Multitask Learning of Longitudinal Circulating Biomarkers and Clinical Outcomes: Identification of Optimal Machine-Learning and Deep-Learning Models
Abstract
Many circulating biomarkers are assessed at different time intervals during clinical studies. Despite of the success of standard joint models in predicting clinical outcomes using low-dimensional longitudinal data (1-2 biomarkers), significant computational challenges are encountered when applying these techniques to high-dimensional biomarker datasets. Modern machine- or deep-learning models show potential for multiple biomarker processes, but systematic evaluations and applications to high-dimensional data in the clinical settings have yet to be reported. We aimed to enhance the scalability of joint modeling and provide guidance on optimal approaches for high-dimensional biomarker data and outcomes. We evaluated multiple deep-learning and machine-learning models using 24 clinical biomarkers and survival data from the SQUIRE trial, a phase 3 randomized clinical trial investigating necitumumab and standard gemcitabine/cisplatin treatment in patients with squamous non-small-cell lung cancer (NSCLC). Overall, we confirmed that longitudinal models enabled more accurate prediction of patients survival compared to those solely based on baseline information. Coupling multivariate functional principal component analysis (MFPCA) with Cox regression (MFPCA-Cox) provided the highest predictive discrimination and accuracy for the NSCLC patients with AUC values of 0.7 - >0.8 at various landmark time points and prediction timeframes, outperforming recent advanced Transformer and convolutional neural network deep-learning algorithms (TransformerJM and Match-Net, respectively). In conclusion, we identified that MFPCA-Cox represents a robust and versatile joint modeling algorithm for high-dimensional biomarker longitudinal data with irregular and missing data, capturing complex relationships within the data, yielding accurate predictions for both longitudinal biomarkers and survival outcomes, and gaining insights into the underlying dynamics.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Predicting the prognosis of non-small cell lung cancer by integrating microarray and clinical data with deep learning
Yu‐Heng Lai, Weining Chen, … Semon Wu·bioRxiv·Oct 18, 2019
- Towards a Survival Risk Prediction Model for Metastatic NSCLC Patients on Durvalumab Using Whole-Lung CT Radiomics
Kedar A. Patwardhan, Harish RaviPrakash, … Joachim Reischl·Frontiers in ImmunologyPeer-reviewed·Jun 10, 2024
- Integrating Knowledge Graphs into Machine Learning Models for Survival Prediction and Biomarker Discovery in Patients with Non-Small-Cell Lung Cancer
Chao Fang, Gustavo Arango-Argoty, … Natasha Markuzon·bioRxiv·Feb 29, 2024
- An Interpretable Deep Learning Framework for Biomarker Discovery in Complex Disease Survival Outcomes
Shiyu Wan, Xinlei Mi, … Baiming Zou·bioRxiv·Sep 30, 2025
- Predicting clinical outcomes from large scale cancer genomic profiles with deep survival models
Safoora Yousefi, Fatemeh Amrollahi, … Lee Cooper·Scientific ReportsPeer-reviewed·Sep 11, 2017
- A Community Challenge to Predict Clinical Outcomes After Immune Checkpoint Blockade in Non-Small Cell Lung Cancer
M. Mason, O. Lapuente-Santana, … B. G. Vincent·Journal of Translational MedicinePeer-reviewed·Feb 21, 2024